Zhong Guo Xin Wen Wang·2025-11-05 07:43Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, showcasing innovative products from various multinational pharmaceutical companies [1] - Eli Lilly presented several innovative drugs, including the oral selective estrogen receptor degrader Imlunestrant for breast cancer and the injectable tirzepatide for cardiovascular metabolic health, marking their debut at the expo [1] - Bayer displayed 26 highlight exhibits across a 800 square meter booth, focusing on innovations in healthcare and agricultural technology [1][2] - Merck showcased approximately 30 approved drugs and vaccines in China, including several innovative medicines and new indications, with plans to introduce over 40 new products and indications in the next five years [2] Company Highlights - Eli Lilly emphasized the acceleration of innovative products and indications in the Chinese market, highlighting collaboration with government, clinical institutions, and industry partners [1] - Bayer's immersive booth design and educational activities aimed to provide a tangible experience of cutting-edge technological innovations [2] - Merck's participation in CIIE has led to the approval of multiple investigational drugs in China, enhancing treatment options for patients with antibiotic-resistant infections and rare diseases [2]